Odonate, Inc.

ODT

US6760793041

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 21:30:48 09/05/2024 BST			5-day change	1st Jan Change
2,850 ^USD	-83.34%		-83.34%	-81.00%

2023	North American Morning Briefing : Recession Threat Grows as Further Tightening Likely	DJ
2023	North American Morning Briefing : Stock Futures -2-	DJ

Odonate Therapeutics, Inc. authorizes a Buyback Plan.

November 16, 2021

The Board of Directors of Odonate Therapeutics, Inc. has authorized a buyback plan on November 17, 2021.

Latest news about Odonate, Inc.

North American Morning Briefing : Recession Threat Grows as Further Tightening Likely	23/06/23	DJ
North American Morning Briefing : Stock Futures -2-	16/06/23	DJ
North American Morning Briefing : Caution Ahead of Fed, Inflation Data to Hold Back Stocks	09/06/23	DJ
North American Morning Briefing : Stock Futures -2-	02/06/23	DJ
North American Morning Briefing : Investors Await -2-	26/05/23	DJ
North American Morning Briefing : Powell on Tap -2-	19/05/23	DJ
North American Morning Briefing : Hopes of Easing -2-	12/05/23	DJ
North American Morning Briefing : Caution -2-	14/04/23	DJ
North American Morning Briefing : Stock Futures -2-	20/05/22	DJ
North American Morning Briefing : Tech Futures -2-	13/05/22	DJ
North American Morning Briefing : Stocks Waver, -3-	12/04/22	DJ
North American Morning Briefing : Stocks to Open -3-	22/02/22	DJ
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P Global BMI Index	20/01/22	CI
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P TMI Index	20/01/22	CI
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from NASDAQ Composite Index	17/01/22	CI
Top Midday Decliners	07/01/22	MT
Odonate Therapeutics Gets Nasdaq Notice to Delist Shares	07/01/22	MT
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from NASDAQ Biotechnology Index	17/12/21	CI
Insider Sell: Odonate Therapeutics	22/11/21	MT
Odonate Therapeutics Plans Share Buybacks After Halting Development of Breast Cancer Drug	17/11/21	MT
Odonate Therapeutics, Inc. announces an Equity Buyback for 20,000,000 shares, representing 51.95% of its issued share capital.	17/11/21	CI
Odonate Therapeutics, Inc. authorizes a Buyback Plan.	16/11/21	CI
Odonate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	10/11/21	CI
North American Morning Briefing : Stock Futures -3-	10/11/21	DJ
Odonate Therapeutics, Inc. Announces Termination of Joseph O’Connell as Chief Medical Officer	05/08/21	CI

Odonate, Inc., formerly Odonate Therapeutics, Inc., is a pharmaceutical company. The Company is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The Company is no longer in development of tesetax.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ODONATE, INC.	-81.00%	48.56M
ELI LILLY AND COMPANY	+32.36%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.40%	358B
MERCK & CO., INC.	+19.46%	328B
ABBVIE INC.	+3.50%	283B
ASTRAZENECA PLC	+16.34%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+8.62%	165B

Other Pharmaceuticals

Odonate, Inc.

Equities

ODT

US6760793041

Pharmaceuticals

Odonate Therapeutics, Inc. authorizes a Buyback Plan.

Latest news about Odonate, Inc.

Chart Odonate, Inc.

Company Profile

Sector Other Pharmaceuticals